Grossman J, Banov C, Boggs P, Bronsky E A, Dockhorn R J, Druce H, Findlay S R, Georgitis J W, Hampel F C, Kaiser H
J Allergy Clin Immunol. 1995 May;95(5 Pt 2):1123-7. doi: 10.1016/s0091-6749(95)70216-4.
To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms.
